{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:07:27Z","timestamp":1788829647501,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05253-0","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T02:15:18Z","timestamp":1782008118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bioinformatic analysis reveals the potential association of ESRP1 with the splicing of cytoskeleton-associated genes in doxorubicin-resistant MCF7 breast cancer cells"],"prefix":"10.1007","volume":"17","author":[{"given":"Jing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingling","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"issue":"2","key":"5253_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2021.0459","volume":"83","author":"C Katsura","year":"2022","unstructured":"Katsura C, Ogunmwonyi I, Kankam HKN, Saha S. Breast cancer: presentation, investigation and management. Br J Hosp Med. 2022;83(2):1\u20137. https:\/\/doi.org\/10.12968\/hmed.2021.0459.","journal-title":"Br J Hosp Med"},{"key":"5253_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40659-017-0140-9","author":"M Akram","year":"2017","unstructured":"Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017. https:\/\/doi.org\/10.1186\/s40659-017-0140-9.","journal-title":"Biol Res"},{"key":"5253_CR3","doi-asserted-by":"publisher","unstructured":"Liao L. Inequality in breast cancer: global statistics from 2022 to 2050.Breast. 2025 Feb;79:103851 https:\/\/doi.org\/10.1016\/j.breast.2024.103851","DOI":"10.1016\/j.breast.2024.103851"},{"key":"5253_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108800","volume":"114","author":"X Ji","year":"2019","unstructured":"Ji X, Lu Y, Tian H, Meng X, Wei M, Cho WC. Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother. 2019;114:108800.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"5253_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/10611869609015970","volume":"4","author":"P Tardi","year":"1996","unstructured":"Tardi P, Boman N, Cullis P. Liposomal doxorubicin. J Drug Target. 1996;4(3):129\u201340.","journal-title":"J Drug Target"},{"issue":"1","key":"5253_CR6","first-page":"456409","volume":"2013","author":"J Lao","year":"2013","unstructured":"Lao J, Madani J, Pu\u00e9rtolas T, et al. Liposomal doxorubicin in the treatment of breast cancer patients: a review. J drug delivery. 2013;2013(1):456409.","journal-title":"J drug delivery"},{"key":"5253_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.708066","volume":"9","author":"X Wang","year":"2021","unstructured":"Wang X, Yan J, Shen B, Wei G. Integrated chromatin accessibility and transcriptome landscapes of doxorubicin-resistant breast cancer cells. Front Cell Dev Biol. 2021;9:708066.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"5253_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/1078155219877931","volume":"26","author":"HS Al-malky","year":"2019","unstructured":"Al-malky HS, Al Harthi SE, Osman A-M. Major obstacles to doxorubicin therapy: cardiotoxicity and drug resistance. J Oncol Pharm Pract. 2019;26(2):434\u201344. https:\/\/doi.org\/10.1177\/1078155219877931.","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"5253_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41419-022-04783-z","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Feng X, Yuan Y, Jiang J, Zhang P, Zhang B. Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage. Cell Death Dis. 2022;13(4):338.","journal-title":"Cell Death Dis"},{"key":"5253_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120463","volume":"298","author":"MDA Paskeh","year":"2022","unstructured":"Paskeh MDA, Saebfar H, Mahabady MK, et al. Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy. Life Sci. 2022;298:120463.","journal-title":"Life Sci"},{"issue":"10","key":"5253_CR11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/jmcb\/mjz033","volume":"11","author":"Q Yang","year":"2019","unstructured":"Yang Q, Zhao J, Zhang W, Chen D, Wang Y. Aberrant alternative splicing in breast cancer. J Mol Cell Biol. 2019;11(10):920\u20139.","journal-title":"J Mol Cell Biol"},{"issue":"12","key":"5253_CR12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/ng.259","volume":"40","author":"Q Pan","year":"2008","unstructured":"Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008;40(12):1413\u20135.","journal-title":"Nat Genet"},{"key":"5253_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.gde.2017.10.001","volume":"48","author":"Z Siegfried","year":"2018","unstructured":"Siegfried Z, Karni R. The role of alternative splicing in cancer drug resistance. Curr Opin Genet Dev. 2018;48:16\u201321. https:\/\/doi.org\/10.1016\/j.gde.2017.10.001.","journal-title":"Curr Opin Genet Dev"},{"key":"5253_CR14","doi-asserted-by":"publisher","unstructured":"Du J-X, Luo Y-H, Zhang S-J, et al. Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1. J Exp Clin Cancer Res. 2021;40(1). https:\/\/doi.org\/10.1186\/s13046-021-01978-8.","DOI":"10.1186\/s13046-021-01978-8"},{"issue":"14","key":"5253_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj4009","volume":"10","author":"L Deng","year":"2024","unstructured":"Deng L, Liao L, Zhang Y-L, et al. SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1. Sci Adv. 2024;10(14):eadj4009.","journal-title":"Sci Adv"},{"key":"5253_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/genes8100217","author":"N Mart\u00ednez-Montiel","year":"2017","unstructured":"Mart\u00ednez-Montiel N, Anaya-Ruiz M, P\u00e9rez-Santos M, Mart\u00ednez-Contreras R. Alternative splicing in breast cancer and the potential development of therapeutic tools. Genes Basel. 2017. https:\/\/doi.org\/10.3390\/genes8100217.","journal-title":"Genes Basel"},{"key":"5253_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.canlet.2020.11.043","volume":"501","author":"J-X Du","year":"2021","unstructured":"Du J-X, Zhu G-Q, Cai J-L, et al. Splicing factors: insights into their regulatory network in alternative splicing in cancer. Cancer Lett. 2021;501:83\u2013104.","journal-title":"Cancer Lett"},{"key":"5253_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/bs.ircmb.2016.06.003","volume":"327","author":"E-L G\u00f6ttgens","year":"2016","unstructured":"G\u00f6ttgens E-L, Span P, Zegers M. Roles and regulation of epithelial splicing regulatory proteins 1 and 2 in epithelial\u2013mesenchymal transition. Int Rev Cell Mol Biol. 2016;327:163\u201394.","journal-title":"Int Rev Cell Mol Biol"},{"key":"5253_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01757-8","author":"C Li","year":"2023","unstructured":"Li C, Yin Y, Tao R, et al. ESRP1-driven alternative splicing of CLSTN1 inhibits the metastasis of gastric cancer. Cell Death Discov. 2023. https:\/\/doi.org\/10.1038\/s41420-023-01757-8.","journal-title":"Cell Death Discov"},{"issue":"9","key":"5253_CR20","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2174\/1568009620666200621153831","volume":"20","author":"Y Vadlamudi","year":"2020","unstructured":"Vadlamudi Y, Dey DK, Kang SC. Emerging multi-cancer regulatory role of ESRP1: orchestration of alternative splicing to control EMT. Curr Cancer Drug Targets. 2020;20(9):654\u201365.","journal-title":"Curr Cancer Drug Targets"},{"issue":"14","key":"5253_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147835","volume":"23","author":"J Elhasnaoui","year":"2022","unstructured":"Elhasnaoui J, Ferrero G, Miano V, et al. A regulatory axis between epithelial splicing regulatory proteins and estrogen receptor \u03b1 modulates the alternative transcriptome of luminal breast cancer. Int J Mol Sci. 2022;23(14):7835.","journal-title":"Int J Mol Sci"},{"key":"5253_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113347","author":"D Mukhopadhyay","year":"2023","unstructured":"Mukhopadhyay D, Goel HL, Xiong C, et al. The calcium channel TRPC6 promotes chemotherapy-induced persistence by regulating integrin \u03b16 mRNA splicing. Cell Rep. 2023;42(11) . https:\/\/doi.org\/10.1016\/j.celrep.2023.113347","journal-title":"Cell Rep"},{"issue":"17","key":"5253_CR23","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884\u201390. https:\/\/doi.org\/10.1093\/bioinformatics\/bty560.","journal-title":"Bioinformatics"},{"issue":"1","key":"5253_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics Jan 1. 2013;29(1):15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635.","journal-title":"Bioinformatics Jan 1"},{"issue":"sup1","key":"5253_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/15476286.2021.1940037","volume":"18","author":"C Cheng","year":"2021","unstructured":"Cheng C, Liu L, Bao Y, et al. SUVA: splicing site usage variation analysis from RNA-seq data reveals highly conserved complex splicing biomarkers in liver cancer. RNA Biol. 2021;18(sup1):157\u201371.","journal-title":"RNA Biol"},{"issue":"12","key":"5253_CR26","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8.","journal-title":"Genome Biol"},{"issue":"1","key":"5253_CR27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.celrep.2018.01.088","volume":"23","author":"M Seiler","year":"2018","unstructured":"Seiler M, Peng S, Agrawal AA, et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep. 2018;23(1):282-296 e4. https:\/\/doi.org\/10.1016\/j.celrep.2018.01.088.","journal-title":"Cell Rep"},{"key":"5253_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2021.100141","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation NY. 2021. https:\/\/doi.org\/10.1016\/j.xinn.2021.100141.","journal-title":"Innovation NY"},{"issue":"4","key":"5253_CR29","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","volume":"28","author":"S Heinz","year":"2010","unstructured":"Heinz S, Benner C, Spann N, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;28(4):576\u201389. https:\/\/doi.org\/10.1016\/j.molcel.2010.05.004.","journal-title":"Mol Cell"},{"key":"5253_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.canlet.2020.11.043","volume":"501","author":"J-X Du","year":"2021","unstructured":"Du J-X, Zhu G-Q, Cai J-L, et al. Splicing factors: insights into their regulatory network in alternative splicing in cancer. Cancer Lett. 2021;501:83\u2013104. https:\/\/doi.org\/10.1016\/j.canlet.2020.11.043.","journal-title":"Cancer Lett"},{"issue":"6","key":"5253_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103580","volume":"28","author":"JB Bertoldo","year":"2023","unstructured":"Bertoldo JB, M\u00fcller S, H\u00fcttelmaier S. RNA-binding proteins in cancer drug discovery. Drug Discov Today. 2023;28(6):103580.","journal-title":"Drug Discov Today"},{"key":"5253_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03180-6","author":"MJ Kwon","year":"2023","unstructured":"Kwon MJ. Role of epithelial splicing regulatory protein 1 in cancer progression. Cancer Cell Int. 2023. https:\/\/doi.org\/10.1186\/s12935-023-03180-6.","journal-title":"Cancer Cell Int"},{"key":"5253_CR33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bcp.2016.11.005","volume":"123","author":"WS Kwon","year":"2017","unstructured":"Kwon WS, Rha SY, Jeung HC, et al. ABCB1 2677G\u2009>\u2009T\/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition. Biochem Pharmacol Jan 1. 2017;123:73\u201384. https:\/\/doi.org\/10.1016\/j.bcp.2016.11.005.","journal-title":"Biochem Pharmacol Jan 1"},{"issue":"3","key":"5253_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.21873\/cdp.10032","volume":"1","author":"C Desd","year":"2021","unstructured":"Desd C, Martello CL, Cadore NA, Ferreira HB, Zaha A, Monteiro KM. Proteomic analysis of the non-genetic response to Cisplatin in lung cancer cells. Cancer Diagn Progn. 2021;1(3):235\u201343. https:\/\/doi.org\/10.21873\/cdp.10032.","journal-title":"Cancer Diagn Progn"},{"key":"5253_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cells9071691","author":"J Kim","year":"2020","unstructured":"Kim J, Cheong JH. Role of mitochondria-cytoskeleton interactions in the regulation of mitochondrial structure and function in cancer stem cells. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9071691.","journal-title":"Cells"},{"issue":"9","key":"5253_CR36","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1042\/bcj20190123","volume":"12","author":"SS Prassanawar","year":"2019","unstructured":"Prassanawar SS, Panda D. Tubulin heterogeneity regulates functions and dynamics of microtubules and plays a role in the development of drug resistance in cancer. Biochem J. 2019;12(9):1359\u201376. https:\/\/doi.org\/10.1042\/bcj20190123.","journal-title":"Biochem J"},{"key":"5253_CR37","doi-asserted-by":"publisher","DOI":"10.1101\/2024.07.08.602566","author":"DF Moakley","year":"2024","unstructured":"Moakley DF, Zhang C. Oncogenic NOVA1 expression dysregulates alternative splicing in breast cancer. bioRxiv[Preprint]. 2024 Jul 10:2024.07.08.602566. https:\/\/doi.org\/10.1101\/2024.07.08.602566","journal-title":"bioRxiv"},{"issue":"1","key":"5253_CR38","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11010-020-03904-6","volume":"476","author":"Y Cao","year":"2021","unstructured":"Cao Y, Zhang F, Wang H, et al. LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p\/Nova1 axis. Mol Cell Biochem. 2021;476(1):279\u201392.","journal-title":"Mol Cell Biochem"},{"issue":"9","key":"5253_CR39","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1158\/1078-0432.CCR-16-2728","volume":"23","author":"AE Kudinov","year":"2017","unstructured":"Kudinov AE, Karanicolas J, Golemis EA, Boumber Y. Musashi RNA-binding proteins as cancer drivers and novel therapeutic targets. Clin Cancer Res. 2017;23(9):2143\u201353.","journal-title":"Clin Cancer Res"},{"key":"5253_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17295","author":"B Sah","year":"2024","unstructured":"Sah B, Singh J, Shen Y, et al. Loss of CELF2 promotes skin tumorigenesis and increases drug resistance. Int J Dermatol. 2025 Jan;64(1):101-110 . https:\/\/doi.org\/10.1111\/ijd.17295","journal-title":"Int J Dermatol"},{"issue":"39","key":"5253_CR41","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1038\/s41388-020-01429-2","volume":"39","author":"K Shah","year":"2020","unstructured":"Shah K, Gagliano T, Garland L, et al. Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing. Oncogene. 2020;39(39):6172\u201389.","journal-title":"Oncogene"},{"issue":"3","key":"5253_CR42","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1042\/BST20221124","volume":"51","author":"JM Derham","year":"2023","unstructured":"Derham JM, Kalsotra A. The discovery, function, and regulation of epithelial splicing regulatory proteins (ESRP) 1 and 2. Biochem Soc Trans. 2023;51(3):1097\u2013109.","journal-title":"Biochem Soc Trans"},{"issue":"5","key":"5253_CR43","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.80921","volume":"19","author":"L Yang","year":"2023","unstructured":"Yang L, Yan B, Qu L, et al. IGF2BP3 regulates TMA7-mediated autophagy and cisplatin resistance in laryngeal cancer via m6A RNA methylation. Int J Biol Sci. 2023;19(5):1382.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"5253_CR44","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/cam4.1296","volume":"7","author":"Y Matsumoto","year":"2018","unstructured":"Matsumoto Y, Itou J, Sato F, Toi M. SALL4-KHDRBS3 network enhances stemness by modulating CD 44 splicing in basal\u2010like breast cancer. Cancer Med. 2018;7(2):454\u201362.","journal-title":"Cancer Med"},{"key":"5253_CR45","doi-asserted-by":"publisher","first-page":"e02734","DOI":"10.7554\/eLife.02734","volume":"3","author":"S Vanharanta","year":"2014","unstructured":"Vanharanta S, Marney CB, Shu W, et al. Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer. eLife. 2014;3:e02734.","journal-title":"eLife"},{"issue":"11","key":"5253_CR46","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1158\/1541-7786.MCR-22-0123","volume":"20","author":"D-S Kim","year":"2022","unstructured":"Kim D-S, Camacho CV, Setlem R, et al. Functional characterization of lncRNA152 as an angiogenesis-inhibiting tumor suppressor in triple-negative breast cancers. Mol Cancer Res. 2022;20(11):1623\u201335.","journal-title":"Mol Cancer Res"},{"key":"5253_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154435","volume":"245","author":"C Xu","year":"2023","unstructured":"Xu C, Sun W, Liu J, Pu H, Li Y. Circ_RBM23 knockdown suppresses chemoresistance, proliferation, migration and invasion of sorafenib-resistant HCC cells through miR-338\u20133p\/RAB1B axis. Pathol Res Pract. 2023;245:154435.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"5253_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33786-9","volume":"28","author":"J Lee","year":"2022","unstructured":"Lee J, Pang K, Kim J, et al. ESRP1-regulated isoform switching of LRRFIP2 determines metastasis of gastric cancer. Nat Commun. 2022;28(1):6274. https:\/\/doi.org\/10.1038\/s41467-022-33786-9.","journal-title":"Nat Commun"},{"issue":"3","key":"5253_CR49","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.18632\/aging.202295","volume":"13","author":"M Zheng","year":"2021","unstructured":"Zheng M, Niu Y, Bu J, et al. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-\u03b2\/Smad signaling. Aging. 2021;13(3):3554.","journal-title":"Aging"},{"issue":"2","key":"5253_CR50","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201846078","volume":"20","author":"Y G\u00f6kmen-Polar","year":"2019","unstructured":"G\u00f6kmen-Polar Y, Neelamraju Y, Goswami CP, et al. Splicing factor ESRP 1 controls ER\u2010positive breast cancer by altering metabolic pathways. EMBO Rep. 2019;20(2):e46078.","journal-title":"EMBO Rep"},{"issue":"11","key":"5253_CR51","doi-asserted-by":"publisher","first-page":"10896","DOI":"10.18632\/aging.103303","volume":"8","author":"M Chen","year":"2020","unstructured":"Chen M, Zeng J, Chen S, et al. SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK\/STAT3 signaling pathway. Aging (Albany NY). 2020;8(11):10896\u2013911. https:\/\/doi.org\/10.18632\/aging.103303.","journal-title":"Aging (Albany NY)"},{"key":"5253_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174401","volume":"15","author":"H Wu","year":"2021","unstructured":"Wu H, Chen S, Liu C, et al. SPTBN1 inhibits growth and epithelial-mesenchymal transition in breast cancer by downregulating miR-21. Eur J Pharmacol. 2021;15:909:174401. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174401.","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"5253_CR53","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2217\/bmm-2019-0504","volume":"14","author":"W Qi","year":"2020","unstructured":"Qi W, Zhang Q. Gene\u2019s co-expression network and experimental validation of molecular markers associated with the drug resistance of gastric cancer. Biomark Med. 2020;14(9):761\u201373. https:\/\/doi.org\/10.2217\/bmm-2019-0504.","journal-title":"Biomark Med"},{"issue":"1","key":"5253_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10789-3","volume":"3","author":"W Tang","year":"2023","unstructured":"Tang W, Shao Q, He Z, Zhang X, Li X, Wu R. Clinical significance of nonerythrocytic spectrin Beta 1 (SPTBN1) in human kidney renal clear cell carcinoma and uveal melanoma: a study based on Pan-Cancer analysis. BMC Cancer. 2023;3(1):303. https:\/\/doi.org\/10.1186\/s12885-023-10789-3.","journal-title":"BMC Cancer"},{"issue":"9","key":"5253_CR55","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.7150\/thno.49819","volume":"11","author":"L Lin","year":"2021","unstructured":"Lin L, Chen S, Wang H, et al. SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma. Theranostics. 2021;11(9):4232\u201350. https:\/\/doi.org\/10.7150\/thno.49819.","journal-title":"Theranostics"},{"issue":"1","key":"5253_CR56","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jcp.28975","volume":"235","author":"S Chen","year":"2020","unstructured":"Chen S, Li J, Zhou P, Zhi X. SPTBN1 and cancer, which links? J Cell Physiol. 2020;235(1):17\u201325. https:\/\/doi.org\/10.1002\/jcp.28975.","journal-title":"J Cell Physiol"},{"key":"5253_CR57","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.2147\/ott.S102713","volume":"9","author":"L Hong","year":"2016","unstructured":"Hong L, Pan F, Jiang H, et al. miR-125b inhibited epithelial-mesenchymal transition of triple-negative breast cancer by targeting MAP2K7. Onco Targets Ther. 2016;9:2639\u201348. https:\/\/doi.org\/10.2147\/ott.S102713.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"5253_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03466-9","volume":"44","author":"S Alexandrou","year":"2025","unstructured":"Alexandrou S, Lee CS, Fernandez KJ, et al. JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4\/6 inhibition in ER+ breast cancer. J Exp Clin Cancer Res. 2025;(1):244. https:\/\/doi.org\/10.1186\/s13046-025-03466-9.","journal-title":"J Exp Clin Cancer Res"},{"key":"5253_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168375","author":"B Benoit","year":"2021","unstructured":"Benoit B, Baillet A, Po\u00fcs C. Cytoskeleton and associated proteins: pleiotropic JNK substrates and regulators. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22168375.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5253_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-019-0486-4","volume":"27","author":"NJ Chew","year":"2020","unstructured":"Chew NJ, Nguyen EV, Su SP, et al. FGFR3 signaling and function in triple negative breast cancer. Cell Commun Signal. 2020;27(1):13. https:\/\/doi.org\/10.1186\/s12964-019-0486-4.","journal-title":"Cell Commun Signal"},{"key":"5253_CR61","doi-asserted-by":"publisher","DOI":"10.1172\/jci173757","author":"MK Chen","year":"2025","unstructured":"Chen MK, Yamaguchi H, Gao Y, et al. FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1\/MRE11-mediated DNA repair in breast cancer models. J Clin Invest. 2025. https:\/\/doi.org\/10.1172\/jci173757.","journal-title":"J Clin Invest"},{"issue":"6","key":"5253_CR62","doi-asserted-by":"publisher","first-page":"214","DOI":"10.4161\/bioa.22332","volume":"2","author":"KB Szarama","year":"2012","unstructured":"Szarama KB, Stepanyan R, Petralia RS, et al. Fibroblast growth factor receptor 3 regulates microtubule formation and cell surface mechanical properties in the developing organ of Corti. Bioarchitecture. 2012;2(6):214\u20139. https:\/\/doi.org\/10.4161\/bioa.22332.","journal-title":"Bioarchitecture"},{"issue":"1","key":"5253_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00756-6","volume":"9","author":"G Wang","year":"2023","unstructured":"Wang G, Li J, Zhu L, et al. Identification of hepatocellular carcinoma-related subtypes and development of a prognostic model: a study based on ferritinophagy-related genes. Discov Oncol. 2023;9(1):147. https:\/\/doi.org\/10.1007\/s12672-023-00756-6.","journal-title":"Discov Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05253-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05253-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05253-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:16:24Z","timestamp":1788826584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05253-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5253"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05253-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,21]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent for participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1305"}}